VistaGen Therapeutics is a California-based biotechnology company that
specializes in the application of human pluripotent stem cell (hPSC) technology
for drug rescue, including predictive toxicology and drug metabolism screening.
The company’s hPSC technology platform, Human Clinical Trials in a Test Tube™,
enables accessibility to the heart and liver safety profile of drug rescue
variants and other new drug candidates with greater speed and precision than
conventional nonclinical testing and technologies used in drug development.
Harnessing this technology’s unique power, VistaGen Therapeutics enables “drug
rescue” of once-promising-but-now-backshelved drug candidates that have been
discontinued by biotechnology or pharmaceutical companies prior to market
approval due to unexpected heart or liver safety concerns.
Recently, the company made an appearance at Noble Financial Capital
Markets’ 9th Annual Equity Conference. The conference took place Wednesday,
January 22, 2014 to Thursday, January 23, 2014 at the Seminole Hard Rock Hotel
in Hollywood, Florida. There, some 100 publicly held companies’ corporate
representatives showcased their companies’ profiles, business strategies, and
outlooks. Investment portfolio managers and equity analysts were on hand to
analyze the representatives’ presentations, ask questions, and get a good
all-around sense of how each business offers growth potential.
At the event, Mr. Shawn K. Singh, J.D., Chief Executive Officer of
VistaGen Therapeutics, said that VistaGen Therapeutics is “changing the game”
in the area of stem cell technology. Noting his experience of 22 years in the
biotech space, Mr. Singh noted that 2014 will be the “breakout year” for the
company.
Having touched upon his executive experience, he then said that the
company is “applying stem cell technology in ways [he] has not seen possible in
the last couple of decades in this space.” According to a Forbes article from
February 2012, the sunk cost of drug development is huge, as the “average drug
developed by a major pharmaceutical company costs at least $4 billion.” Likewise,
the failure of drug development was noted to be staggering and largely
attributable to heart or liver toxicity, with over 50% of drug development
efforts failing due to these medical concerns.
Mr. Singh touched upon the efficacy of Human Clinical Trials in a Test
Tube in combating these sunk cost risks, as the hPSC technology platform
identifies failure potential early in a drug’s development process before too
many cost have been paid. In short, the technology lets pharmaceutical
companies “bring human biology to the forefront of drug development”, thereby
letting them “change the game early” in their drug development stages. He then
went on to discuss other key company focuses and goals for 2014.
The entirety of Mr. Singh’s presentation at the Noble conference can be
found at:
http://noble.mediasite.com/mediasite/Play/7b2df397209e4accad8b01e55857bb431d?catalog=7196f4ed-1981-4e62-afb2-e3a1f13bc7fb
For more information about VistaGen Therapeutics and its technologies,
visit: http://www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment